CN107075574A - 铁调素和微型铁调素类似物及其用途 - Google Patents

铁调素和微型铁调素类似物及其用途 Download PDF

Info

Publication number
CN107075574A
CN107075574A CN201580043057.2A CN201580043057A CN107075574A CN 107075574 A CN107075574 A CN 107075574A CN 201580043057 A CN201580043057 A CN 201580043057A CN 107075574 A CN107075574 A CN 107075574A
Authority
CN
China
Prior art keywords
lys
present
ala
arg
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580043057.2A
Other languages
English (en)
Chinese (zh)
Inventor
格雷戈里·托马斯·伯恩
马克·莱斯利·斯密斯
布莱恩·特洛伊·弗莱德里克
西蒙·文科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of CN107075574A publication Critical patent/CN107075574A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580043057.2A 2014-06-27 2015-06-29 铁调素和微型铁调素类似物及其用途 Pending CN107075574A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018382P 2014-06-27 2014-06-27
US62/018,382 2014-06-27
PCT/US2015/038370 WO2015200916A2 (en) 2014-06-27 2015-06-29 Hepcidin and mini-hepcidin analogues and uses therof

Publications (1)

Publication Number Publication Date
CN107075574A true CN107075574A (zh) 2017-08-18

Family

ID=54938965

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580043057.2A Pending CN107075574A (zh) 2014-06-27 2015-06-29 铁调素和微型铁调素类似物及其用途

Country Status (10)

Country Link
US (2) US20170313754A1 (enExample)
EP (1) EP3161164A4 (enExample)
JP (1) JP2017523959A (enExample)
KR (1) KR20170043509A (enExample)
CN (1) CN107075574A (enExample)
AU (1) AU2015279571A1 (enExample)
CA (1) CA2953721A1 (enExample)
IL (1) IL249692A0 (enExample)
SG (1) SG11201610799WA (enExample)
WO (1) WO2015200916A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114252627A (zh) * 2020-09-24 2022-03-29 首都医科大学附属北京世纪坛医院 尿液铁调素及其多肽片段在过敏性疾病中的应用
CN114729022A (zh) * 2019-09-03 2022-07-08 领导医疗有限公司 缀合的铁调素模拟物
CN115997130A (zh) * 2020-07-02 2023-04-21 坦佩雷大学注册基金会 基于肾素的铁调素分析

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4944360B2 (ja) 2001-05-25 2012-05-30 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
PL2968443T3 (pl) 2013-03-15 2022-02-07 Protagonist Therapeutics, Inc. Analogi hepcydyny i ich zastosowania
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
CN113621027A (zh) 2014-05-16 2021-11-09 领导医疗有限公司 α4β7整联蛋白硫醚肽拮抗剂
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
AU2015328002A1 (en) 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) * 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN108883154A (zh) * 2016-01-08 2018-11-23 拉卓拉药物公司 施用铁调素的方法
EP3432906A4 (en) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
US20180099023A1 (en) * 2016-09-06 2018-04-12 La Jolla Pharmaceutical Company Methods of treating iron overload
JP2020502169A (ja) * 2016-12-19 2020-01-23 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ ヘプシジンを投与する方法
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
US20200170971A1 (en) * 2017-07-18 2020-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
WO2019157268A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso
PH12021552817A1 (en) 2019-05-07 2022-09-28 Bayer Ag Masp inhibitory compounds and uses thereof
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021062171A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
JP2022549506A (ja) * 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
EP4142732A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
US20230159553A1 (en) 2020-04-28 2023-05-25 Global Blood Therapeutics, Inc Thieno pyrimidines as ferroportin inhibitors
EP4143178A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
CN111560051B (zh) * 2020-05-26 2022-11-25 大连工业大学 一种具有促铁吸收活性的虾源九肽及其应用
US20240018189A1 (en) * 2020-07-28 2024-01-18 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4247403A4 (en) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
WO2022212696A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4355763A4 (en) * 2021-06-14 2025-07-30 Protagonist Therapeutics Inc HEPCIDIN MIMETICS FOR THE TREATMENT OF HEREDITARY HEMOCHROMATOSIS
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CN115703826B (zh) * 2021-08-03 2025-05-06 浙江大学 铁调素改造体及其应用
WO2024059264A1 (en) * 2022-09-15 2024-03-21 Migal Galilee Research Institute Ltd Site-specific activation of regulatory t cells
WO2025224128A1 (en) 2024-04-24 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097461A2 (en) * 2007-02-02 2008-08-14 Amgen Inc Hepcidin and hepcidin antibodies
CN101307085A (zh) * 2007-08-01 2008-11-19 钱忠明 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
CN101358201A (zh) * 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
WO2009027752A3 (en) * 2007-08-24 2009-06-11 Hellenic Pasteur Inst Process for producing hepcidin
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
WO2011149942A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
WO2013086143A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968443T3 (pl) * 2013-03-15 2022-02-07 Protagonist Therapeutics, Inc. Analogi hepcydyny i ich zastosowania

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097461A2 (en) * 2007-02-02 2008-08-14 Amgen Inc Hepcidin and hepcidin antibodies
CN101358201A (zh) * 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085A (zh) * 2007-08-01 2008-11-19 钱忠明 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
WO2009027752A3 (en) * 2007-08-24 2009-06-11 Hellenic Pasteur Inst Process for producing hepcidin
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
WO2011149942A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
WO2013086143A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729022A (zh) * 2019-09-03 2022-07-08 领导医疗有限公司 缀合的铁调素模拟物
CN115997130A (zh) * 2020-07-02 2023-04-21 坦佩雷大学注册基金会 基于肾素的铁调素分析
CN114252627A (zh) * 2020-09-24 2022-03-29 首都医科大学附属北京世纪坛医院 尿液铁调素及其多肽片段在过敏性疾病中的应用

Also Published As

Publication number Publication date
IL249692A0 (en) 2017-02-28
CA2953721A1 (en) 2015-12-30
US20200017566A1 (en) 2020-01-16
US20170313754A1 (en) 2017-11-02
EP3161164A2 (en) 2017-05-03
KR20170043509A (ko) 2017-04-21
AU2015279571A1 (en) 2017-02-02
JP2017523959A (ja) 2017-08-24
EP3161164A4 (en) 2018-04-25
SG11201610799WA (en) 2017-01-27
WO2015200916A2 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
US12269856B2 (en) Hepcidin analogues and uses thereof
US20200017566A1 (en) Hepcidin and mini-hepcidin analogues and uses therof
US12234300B2 (en) Conjugated hepcidin mimetics
WO2022026633A1 (en) Conjugated hepcidin mimetics
CN114729022A (zh) 缀合的铁调素模拟物
TW202304951A (zh) 結合鐵調素模擬物
WO2022212698A1 (en) Conjugated hepcidin mimetics
CN116457000A (zh) 缀合的铁调素模拟物
CN117730089A (zh) 结合型铁调素模拟物
EA048412B1 (ru) Конъюгированные миметики гепсидина

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818

WD01 Invention patent application deemed withdrawn after publication